Related references
Note: Only part of the references are listed.Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).
L. G. Feun et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Small Cell Lung Cancer: Are We Making Progress?
Jonathan E. Dowell
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2010)
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
T-S Yang et al.
BRITISH JOURNAL OF CANCER (2010)
Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
N. Savaraj et al.
CURRENT MOLECULAR MEDICINE (2010)
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
I. K. Demedts et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma
Evan S. Glazer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma
Eisuke Kobayashi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Small Cell Lung Cancer: Past, Present, and Future
Estelamari Rodriguez et al.
CURRENT ONCOLOGY REPORTS (2010)
Targeting metabolic transformation for cancer therapy
Daniel A. Tennant et al.
NATURE REVIEWS CANCER (2010)
Serum deprivation induced autophagy and predominantly an AIF-dependent apoptosis in hippocampal HT22 neurons
S. Steiger-Barraissoul et al.
APOPTOSIS (2009)
ADI, autophagy and apoptosis Metabolic stress as a therapeutic option for prostate cancer
Randie H. Kim et al.
AUTOPHAGY (2009)
Arginine Deiminase as a Novel Therapy for Prostate Cancer Induces Autophagy and Caspase-Independent Apoptosis
Randie H. Kim et al.
CANCER RESEARCH (2009)
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer
Linda J. Nicholson et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 alpha/Sp4
Wen-Bin Tsai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Tumor cell metabolism: Cancer's Achilles' heel
Guido Kroemer et al.
CANCER CELL (2008)
Arginine deprivation as a targeted therapy for cancer
L. Feun et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase
Tawnya L. Bowles et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Cell death and autophagy: Cytokines, drugs, and nutritional factors
Wilfried Burscha et al.
TOXICOLOGY (2008)
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase
Cheol-Yong Yoon et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion
Peter W. Szlosarek et al.
CLINICAL CANCER RESEARCH (2006)
Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase
LJ Shen et al.
CANCER LETTERS (2006)
Analysis of apoptosis by propidium iodide staining and flow cytometry
Carlo Riccardi et al.
NATURE PROTOCOLS (2006)
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies
PA Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of autophagy in cancer development and response to therapy
Y Kondo et al.
NATURE REVIEWS CANCER (2005)
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers - A method for identifying cancers sensitive to arginine deprivation
BJ Dillon et al.
CANCER (2004)
Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells
EJ Noh et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies
F Izzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase
LJ Shen et al.
CANCER LETTERS (2003)
Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties
FW Holtsberg et al.
JOURNAL OF CONTROLLED RELEASE (2002)
Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis
H Gong et al.
LEUKEMIA (2000)